| 依维莫司抗肾细胞癌研究进展 |
| |
| 引用本文： | 陈烨,郑颖,徐利锋.依维莫司抗肾细胞癌研究进展[J].辽宁大学学报(自然科学版),2011,38(1):60-66. |
| |
| 作者姓名： | 陈烨 郑颖 徐利锋 |
| |
| 作者单位： | 辽宁大学药学院,辽宁沈阳,110036 |
| |
| 摘 要： | 依维莫司是一种口服的哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂,临床上常用于预防肾移植和心脏移植手术后的排异反应.近年来发现它对晚期肾细胞癌具有较好疗效,可用于舒尼替尼或者索拉非尼治疗失败的肾癌患者.主要介绍依维莫司的抗肿瘤作用机制及其应用的研究进展.
|
| 关 键 词： | 哺乳动物雷帕霉素靶蛋白 肾细胞癌 依维莫司 |
Everolimus Treated Anti-RCC Current Reserch Progress |
| |
| CHEN Ye,ZHENG Ying,XU Li-feng.Everolimus Treated Anti-RCC Current Reserch Progress[J].Journal of Liaoning University(Natural Sciences Edition),2011,38(1):60-66. |
| |
| Authors: | CHEN Ye ZHENG Ying XU Li-feng |
| |
| Institution: | CHEN Ye,ZHENG Ying,XU Li-feng(College of Pharmaceutical,Liaoning University,Shenyang 110036,China) |
| |
| Abstract: | Everolimus is an orally administered inhibitor of the mammalian target of rapamycin(mTOR),which is commonly used in clinical to prevent renal and heart transplant rejection.In recent years,Everolimus has been found to have better effect on advanced renal cell carcinoma,and can be used for patients with RCC after failure of treatment with sunitinib or sorafenib.This paper mainly introduce the everolimus mechnisim of anti-cancer reserch and its applications. |
| |
| Keywords: | mammalian target of rapamycin renal cell carcinoma Everolimus |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
